Andrei Corina, Zanfirescu Anca, Nițulescu George Mihai, Olaru Octavian Tudorel, Negreș Simona
Faculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Traian Vuia 6, 020956 Bucharest, Romania.
Plants (Basel). 2023 Jan 11;12(2):339. doi: 10.3390/plants12020339.
Diseases such as cancer, neurological pathologies and chronic pain represent currently unmet needs. The existing pharmacotherapeutic options available for treating these conditions are limited by lack of efficiency and/or side effects. Transient receptor potential vanilloid 1 ion channel emerged as an attractive therapeutic target for developing new analgesic, anti-cancer and antiepileptic agents. Furthermore, various natural ingredients were shown to have affinity for this receptor. The aim of this narrative review was to summarize the diverse natural scaffolds of TRPV1 modulators based on their agonistic/antagonistic properties and to analyze the structure-activity relationships between the ligands and molecular targets based on the results of the existing molecular docking, mutagenesis and in vitro studies. We present here an exhaustive collection of TRPV1 modulators grouped by relevant chemical features: vanilloids, guaiacols, phenols, alkylbenzenes, monoterpenes, sesquiterpenoids, alkaloids, etc. The information herein is useful for understanding the key structural elements mediating the interaction with TRPV1 and how their structural variation impacts the interaction between the ligand and receptor. We hope this data will contribute to the design of novel effective and safe TRPV1 modulators, to help overcome the lack of effective therapeutic agents against pathologies with high morbidity and mortality.
癌症、神经病理学疾病和慢性疼痛等疾病目前仍存在未被满足的需求。用于治疗这些病症的现有药物治疗选择受到疗效欠佳和/或副作用的限制。瞬时受体电位香草酸受体1离子通道成为开发新型镇痛、抗癌和抗癫痫药物的一个有吸引力的治疗靶点。此外,各种天然成分已被证明对该受体具有亲和力。本叙述性综述的目的是根据其激动/拮抗特性总结TRPV1调节剂的各种天然支架,并根据现有分子对接、诱变和体外研究结果分析配体与分子靶点之间的构效关系。我们在此展示了按相关化学特征分组的TRPV1调节剂的详尽集合:香草酸类、愈创木酚类、酚类、烷基苯类、单萜类、倍半萜类、生物碱类等。本文中的信息有助于理解介导与TRPV1相互作用的关键结构元件,以及它们的结构变化如何影响配体与受体之间的相互作用。我们希望这些数据将有助于设计新型有效且安全的TRPV1调节剂,以帮助克服针对发病率和死亡率高的病症缺乏有效治疗药物的问题。